Table 81GRADE profile - PFTA versus PFTA plus EMG versus PFTA plus EMG plus NMES

No. of studiesDesignTreatment (n)Control (n)ResultsLimitationsInconsistencyIndirectnessImprecisionOther considerationsQuality
Outcome: Incontinence Impact Questionnaire (IIQ) total score (higher score indicates worse outcomes)
1 McClurg 20063RCTPFTA + EMG +NMES

N=10
PFTA

N=10

PFTA + EMG

N=10
Total score mean (SD)

Weeks 0 vs 9
PFTA vs PFTA + EMG + NMES (P=0.027)

PFTA vs PFTA + EMG (p=0.036)

Week 24
PFTA vs PFTA + EMG + NMES (p=0.040)

PFTA vs PFTA + EMG (ns)
S (i)NNS (ii)NLow
Outcome: Leakage episodes per 24 hr
1 McClurg 20063RCTPFTA + EMG +NMES

N=10
PFTA

N=10

PFTA + EMG

N=10
Week 0 vs 9
PFTA reduction 12 % (week 0 vs 9; p=0.687)
PFTA + EMG 45% (p=0.074)
PFTA + EMG + NMES 68% (p=0.002)
PFTA vs PFTA + EMG + NMES (p=0.014)
Week 0 vs 24
PFTA reduction minimal
PFTA + EMG 58% (p=0.028)
PFTA + EMG + NMES 75% (p=0.003)
PFTA vs PFTA + EMG (p=0.007); PFTA vs PFTA + EMG + NMES (p=0.001)
S (i)NNS (ii)NLow
Outcome: No. incontinent
1 McClurg 20063RCTPFTA + EMG +NMES

N=10
PFTA

N=10

PFTA + EMG

N=10
Week 0 vs 9 vs 24
PFTA 6/10 vs 9/10 (RR0.67 (95%CI0.39 to 1.15) vs 8/10 (RR0.75 (0.41 to 1.36)
PFTA + EMG 8/10 vs 7/10 (RR1.14 (0.69 to 1.90) vs 5/10 (RR1.60 (0.80 to 3.20)
PFTA + EMG + NMES 9/10 vs 7/10 (RR1.29 (0.82 to 2.03) vs 5/10 (RR1.80 (0.94 to 3.46)
S (i)NNS (iii)NLow
Outcome: Nocturia
1 McClurg 20063RCTPFTA + EMG +NMES

N=10
PFTA

N=10

PFTA + EMG

N=10
Nocturia was reduced in all groups by week 9 (p=0.035) maintained, albeit by varying degrees, by week 24S (i)NNS (ii)NLow
Outcome: Post-void residual urine ml
1 McClurg 20063RCTPFTA + EMG +NMES

N=10
PFTA

N=10

PFTA + EMG

N=10
Week 0 vs 9 vs 24
PFTA 90 vs 60 vs 80
PFTA + EMG 160 vs 60 vs 60
PFTA + EMG + NMES 84 vs 60 vs 30
No significant between groups
S (i)NNS (ii)NLow
i
ii

Imprecision could not be assessed because p values/no standard deviations presented

iii

95%CI crosses the MID for either benefit or harm

From: 9, Treatment for stress incontinence

Cover of Urinary Incontinence in Neurological Disease
Urinary Incontinence in Neurological Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease.
NICE Clinical Guidelines, No. 148.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.